January 17th, 2020 | 13:37 CET
Evotec, Memphasys, MorphoSys - Growth Industry Health
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Expert for drug discovery
Evotec claims to be one of the leading suppliers in the field of active ingredient research, drawing on the know-how accumulated over more than two decades. The company has its headquarters in Hamburg and employs more than 2,900 people worldwide. With a share price of EUR 24.65, Evotec's market capitalization is more than EUR 3.6 billion, making it one of the larger companies in the industry.
Innovations in fertility
Memphasys from Australia is still in the early stages of its corporate development and is working on the topic of artificial insemination to offer couples who wish to have children an improved chance of success for a successful pregnancy. The company's product is called FELIX and is currently in the test phase. A major market launch is scheduled for the second half of 2020. The value of the company on the stock exchange currently amounts to EUR 26 million and a successful operative development should have a corresponding impact.
Experience with antibody technologies
With a share price of EUR 118.70, MorphoSys has a market capitalization of EUR 3.8 billion. According to MorphoSys, it has made a name for itself in the pharmaceutical industry with its antibody technologies. The company develops both its own active ingredients and those of its partners. In drug discovery and development, the Company relies primarily on its innovative technologies. Together with its partners, MorphoSys has built a drug pipeline with more than 100 fully human antibody candidates.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.